KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Net Margin (2016 - 2025)

Historic Net Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 25.76%.

  • Acadia Pharmaceuticals' Net Margin rose 126800.0% to 25.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.94%, marking a year-over-year increase of 111100.0%. This contributed to the annual value of 23.64% for FY2024, which is 320800.0% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Net Margin of 25.76% as of Q3 2025, which was up 126800.0% from 10.08% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Net Margin peaked at 55.37% during Q4 2024, and registered a low of 97.95% during Q1 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Net Margin had a median value of 10.98% in 2021 and averaged 12.19%.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -355900bps in 2022, then soared by 616300bps in 2023.
  • Acadia Pharmaceuticals' Net Margin (Quarter) stood at 32.96% in 2021, then rose by 7bps to 30.53% in 2022, then skyrocketed by 165bps to 19.82% in 2023, then soared by 179bps to 55.37% in 2024, then tumbled by -53bps to 25.76% in 2025.
  • Its Net Margin stands at 25.76% for Q3 2025, versus 10.08% for Q2 2025 and 7.77% for Q1 2025.